Pancreatic Cancer Treatment Navigator 2026
The biggest breakthrough in pancreatic cancer history: Daraxonrasib doubles overall survival to 13.2 months. Triple-targeted therapy, IRAK4 immunotherapy, and Whipple surgery — find your molecularly-matched pathway across 7 countries.
Select Your Pancreatic Cancer Subtype
2026 molecular classification: KRAS G12C, KRAS wild-type, and stage-based pathways each require a distinct strategy.
KRAS G12C+ Adenocarcinoma BREAKTHROUGH
Daraxonrasib (oral) — median OS 13.2 months vs 6.7 months chemo. FDA expanded access 2026.
KRAS+ (Triple-Targeted Trial)
KRAS inhibitor + approved drug + proteasome degrader — complete tumor elimination in mice
Non-KRAS Adenocarcinoma
Chemoimmunotherapy + IRAK4 blocker — survival up to 100 days in mice models
Early Stage (0–I)
Whipple surgery + adjuvant chemotherapy — curative intent
Navigate by Treatment Pathway
Detailed comparison of Daraxonrasib, triple-targeted therapy, and IRAK4 immunotherapy access.
Daraxonrasib (KRAS G12C Oral)
Oral tablet targeting KRAS G12C. FDA expanded access 2026. Median OS: 13.2 months.
• India: Trial & expanded access — 2-4 weeks, $40K-$150K
• China: Trial access — 6-10 weeks, $40K-$80K
• Germany: Limited expanded access — 4-6 weeks, €100K-€150K
| Target | KRAS G12C |
| Status | 🔶 FDA Expanded Access (not full approval) |
| Median OS | 13.2 months (vs 6.7 months chemo) |
| Best Country | 🇮🇳 India (fastest, largest cohort) |
Triple-Targeted Therapy (Trial)
KRAS inhibitor + approved lung cancer drug + proteasome degrader. Complete tumor elimination in mice.
• Spain (CNIO): Original trial site
• China: Active trials — 6-10 weeks, $40K-$80K
• India: Emerging trials — 4-8 weeks
| Target | KRAS + proteasome |
| Status | 🔶 Phase 1/2 Trial |
| Outcome (Mice) | Complete elimination, long-term regression |
| Best Country | 🇨🇳 China (trial breadth) |
Daraxonrasib: China vs India Access Comparison
Detailed head-to-head comparison for KRAS G12C+ pancreatic cancer patients seeking Daraxonrasib.
| Parameter | 🇨🇳 China | 🇮🇳 India | Winner |
|---|---|---|---|
| FDA Full Approval | ❌ No (Expanded Access Only) | Equal | |
| NMPA/DCGI Approval | ❌ No | ❌ No | Equal |
| Clinical Trial Access | ✅ Available | ✅ Available | Equal |
| Expanded Access Program | 🔶 Limited (~20-30 patients) | ✅ Active (~50-60 patients) | 🇮🇳 India |
| Trial Enrollment Time | 6-10 weeks | 2-4 weeks | 🇮🇳 India |
| Expanded Access Time | 8-12 weeks | 4-6 weeks | 🇮🇳 India |
| Trial Cohort Size | ~100+ patients | ~150+ patients | 🇮🇳 India |
| Trial Cost | $40,000-$80,000 | $40,000-$80,000 | Equal |
| Expanded Access Cost | $100,000-$150,000 | $100,000-$150,000 | Equal |
| Median OS (Trial) | 10-12 months | 12-14 months | 🇮🇳 India |
| Median OS (Expanded) | 12-14 months | 13-14 months | 🇮🇳 India |
| Language | English + Chinese | English + Hindi | 🇮🇳 India (Easier English) |
| Visa Processing | 5-7 days | 3-7 days | 🇮🇳 India |
🏆 Overall Winner: India
India wins on speed (2-4 weeks vs 6-10 weeks), expanded access availability, cohort size, and median OS. China is preferred only if you need broader trial options including triple-targeted therapy.
Pancreatic Cancer: Country Comparison
Each country plays a distinct role based on Daraxonrasib access, trial availability, and surgical expertise.
India
China
Germany
South Korea
Pancreatic Cancer Decision Matrix
Complete routing: subtype × treatment × best country × budget × urgency.
| Subtype | Optimal Treatment | Best Country | Budget | Urgency |
|---|---|---|---|---|
| KRAS G12C+ Adenocarcinoma | Daraxonrasib (Oral) | 🇮🇳 India | $100K-$150K | High |
| KRAS+ (Trial) | Triple-Targeted Therapy | 🇨🇳 China / 🇮🇳 India | $40K-$80K | Medium |
| Non-KRAS Adenocarcinoma | Chemoimmunotherapy + IRAK4 | 🇩🇪 Germany / 🇺🇸 USA | $20K-$50K | Medium |
| Metastatic Pancreatic | Chemotherapy + Palliative | 🇮🇳 India / 🇨🇳 China | $1,200-$6,400 | High |
| Early Stage (0–I) | Whipple Surgery + Chemo | 🇩🇪 Germany / 🇰🇷 Korea | $20K-$60K | High |
| Locally Advanced (II–III) | Chemo + Radiation ± Surgery | 🇩🇪 Germany / 🇰🇷 Korea | $7K-$25K | High |
Navigation Tools & Required Documents
Essential tools for pancreatic cancer treatment access.
Required Documents Checklist
- Medical letter: Diagnosis, KRAS mutation status
- Pathology report: NGS panel, KRAS G12C confirmation
- Imaging: CT/PET-CT (DICOM format)
- Treatment history: All prior therapies
- Passport + Visa: Required for travel
Timeline Estimator
- India Daraxonrasib trial: 2-4 weeks
- China Daraxonrasib trial: 6-10 weeks
- Germany Whipple surgery: 4-6 weeks
- IRAK4 trial: 4-8 weeks
- Second opinion: 48 hours
Top Hospitals for Daraxonrasib
India: Tata Memorial (Mumbai), Apollo Chennai, AIIMS Delhi, CMC Vellore
China: CARsgen (Guangzhou), Peking University Cancer Hospital, Shanghai Rad-Hanhua
View All Partner HospitalsDisclaimer: This is a decision-support tool, not medical advice. All treatment decisions are made by licensed physicians at partner institutions. Read our full Legal Framework →
Pancreatic Cancer Treatment FAQ
Daraxonrasib has FDA expanded access (2026) for KRAS G12C+ pancreatic adenocarcinoma — not full FDA approval. Median OS: 13.2 months vs 6.7 months with chemotherapy. Available via clinical trials and expanded access programs in India (fastest, 2-4 weeks) and China (6-10 weeks).
India is significantly faster: 2-4 weeks for trial enrollment vs China's 6-10 weeks. For expanded access programs: India 4-6 weeks vs China 8-12 weeks. India also has a larger trial cohort (~150+ vs ~100+ patients) and more active expanded access program (~50-60 vs ~20-30 patients).
Yes, in Phase 1/2 trials. KRAS inhibitor + approved lung cancer drug + proteasome degrader. Complete tumor elimination in mice with long-term regression. Available in Spain (CNIO, original site), China (active trials), and India (emerging trials). Costs: $40,000-$80,000.
Standard immunotherapy alone has low response rates (10-20%) in pancreatic cancer. However, combining immunotherapy with an IRAK4 blocker significantly improves outcomes — survival increased to 100 days in mice models vs 40-50 days with chemo alone. Phase 1 trials active in USA, Germany, and Korea.
Yes, Whipple surgery is the standard curative treatment for resectable (Stage 0-I) pancreatic cancer, followed by adjuvant chemotherapy. Germany, Korea, and Singapore have the highest surgical volumes and best outcomes for complex pancreatic surgery. Costs: $20,000-$60,000.
Ready to Find Your Pancreatic Cancer Treatment Path?
Submit your case for a free, no-obligation molecular assessment. Our GI oncology team will match your KRAS status and stage with the optimal destination and pathway within 48 hours.
Submit Your Case NowFree • Confidential • 48-Hour Response • No Obligation
One Response